The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42.
Frontline plc
FRO · the NYSE · USD · Market cap $10.1B
FAIL · Does not pass the screenPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price44.75 USD at the 19 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 19 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.42)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $39.60 to $65.93, base estimate $55.12 (screen dated 2026-11-19).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.42, read 2026-11-18
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Frontline plc holds its Distribution at $44.75. Consolidating, no directional conviction, held for 10 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 10 days |
| Price at the screen | $44.75 |
| Valuation | 6.83 trailing · 7.30 forward price to earnings |
| Values screen | FAIL |
| Beta | 0.18 |
Five Screens: FRO's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 37.15% | Below 33% | Fail |
| Interest-bearing cash | 3.07% | Below 33% | Pass |
| Receivables | 0.00% | Below 49% | Pass |
| Revenue purity | 0.80% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Frontline's business is in a permissible area, but its interest-bearing debt is about 37% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when FRO's ethical verdict changes
Today FRO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 19 Nov 2026: it trades at roughly a 19% discount to our $55.12 fair value, moderate competitive moat, 96.50% revenue growth.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. A 18.8% discount to the base estimate.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits +28% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $55.12, with a range of $39.60 to $65.93, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain WordsTanker profits look tempting at peak cycle
Oil moves across oceans in fleets that earn fortunes when energy prices spike and then watch those same earnings collapse when demand cools. Frontline sits right in that flow, posting 67% revenue growth and a 40% profit margin with 35% return on equity. The forward multiple of 10.3 times earnings appears cheap next to those figures and a moderate moat, yet the shares trade almost exactly at our fair value with almost no margin of safety.
Those headline numbers reflect conditions at the top of the cycle rather than a durable edge. Four analysts see a median target of $42, but the business remains exposed to freight rate swings that have crushed similar operators in past downturns. Low multiples on peak earnings have often proved a warning sign, not a bargain, in this industry.
The ethical screen also flags the debt ratio, ruling the name out regardless of the near-term cash flow. Analysis, not advice.
| Forward P/E | 7.3xcheap for a company growing this fast |
| Trailing P/E | 6.8xvery cheap relative to earnings |
| EPS, trailing | 6.67 |
| EPS, forward | 6.24 |
| Revenue growth | +96.5%growing very fast |
| Profit margin | 54.8%highly profitable on every dollar of sales |
| Return on equity | 53.9%an exceptional return on shareholder capital |
| FCF yield | 2.80% |
| Dividend yield | 11.87% |
| Debt to equity | 0.77moderate, manageable leverage |
| Current ratio | 1.87healthy short-term liquidity |
| Beta | 0.18barely tracks the market's swings |
| Short interest, float | 0.07% |
| 52-week range | 20.47 - 59.75 |
| Moat | MODERATE |
| Market cap | $10.1B |
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 20.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42. Since the last review it its composite score rose.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 14.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42. Since the last review it its composite score rose.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 20.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 20.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it buy, with a mean price target of $42.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- FRO – Invitation to Q3 2026 Results Conference Call and Webcast Yahoo Finance · 7d ago
- Can INSW's Record Q3 and Strong Q4 Bookings Sustain Cash Returns? Yahoo Finance · 8d ago
- INSW Dips 12.4% in a Week as Tanker Risks Challenge the Bull Case Yahoo Finance · 8d ago
- Is INSW Worth Buying as Earnings Surge but Tanker Risks Stay High? Yahoo Finance · 8d ago
- Revisiting Former Stock Picks Frontline, OneSpaWorld Holdings, Reddit Yahoo Finance · 8d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $50.72 | -12.4% | · | $876 | -12.4% |
| 2 months | $51.42 | -13.6% | · | $864 | -13.6% |
| 3 months | $40.81 | +8.8% | $3.41 | $1,172 | +17.2% |
| 6 months | $33.33 | +33.3% | $4.96 | $1,481 | +48.1% |
| 1 year | $22.42 | +98.0% | $5.99 | $2,248 | +124.8% |
| 2 years | $16.77 | +164.9% | $6.71 | $3,049 | +204.9% |
| 3 years | $16.67 | +166.4% | $8.62 | $3,181 | +218.1% |
| 5 years | $4.68 | +848.1% | $11.34 | $11,902 | +1,090.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever FRO does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.